Helping people in need !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.reddit.com/r/ATHX/comments/u6fxjh/sa_article_athersys_hero_or_zero/?%24deep_link=true
https://seekingalpha.com/article/4501908-athersys-hero-or-zero-opportunity?mailingid=27404997&messageid=2800&serial=27404997.2901&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=27404997.2901
Plenty of time left at least 5-6 months to go !!!!
GET A LIFE SHORTY !!!!!!!!!!
Just in case if you missed a good read ... GOOD LUCK LONGS
https://finance.yahoo.com/news/global-stem-cell-market-report-091600805.html
https://www.reddit.com/r/ATHX/comments/tyh6xh/stem_cells_restore_lost_function_in_traumatic/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
https://www.neurologylive.com/view/sb623-potential-for-traumatic-brain-injury-peter-mcallister
It would have been helpful if Helios could adopt some value from USA, or other, trail sites phase 3 - ARDS. Incorporate data into Helios NDA. They should have thought that the main trial doctor appointed by Helios to be responsible for the trials would have discussed the size of the trial / number of patients, over the course of the one year or so. One of the reason's Helios stock prices dropped well before the bad news is released.
They have up to September !! What's your point ??? Or should I say .. LOL LOL LOL
Healios Business Briefing for Institutional Investors ...
https://ssl4.eir-parts.net/doc/4593/tdnet/2103951/00.pdf
It's been a LONG 15-year journey which Athersys will be closing in on commercialization of its stem cell therapy etc. ... GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/twfvc6/athersys_closing_in_on_commercialization_of_its/?%24deep_link=true&correlation_id=22cbc1d9-be1b-49dc-8370-e92dc5a5e194&post_fullname=t3_twfvc6&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22Q0U7EIBBFv6a%2BtbXQXe0mG7OJMX6AD74RFqbtRAoEplb9eqet%2B2YC4ebcuczASBTzqa4TWItU6Rgrh%2F6jlvGpEK2MZ1A637EMCQf02qk5ufO4pgp5KcQLr2VZqr%2B8CRODxPvy9vrOB4MJPGWWtPSf5shC0wgpf2dlXMjoB4VeBa%2B20mRQO%2FzRhExCr3CLFpL7tBYgqnW6Qj5TmqEQRxNSArdXo2UuhLmaxnblFZpr2XbWlI%2Fy4b6ETlhz0AdoupZzMWRS%2Feyc1xOs10l1G2%2F30Fv4YqNhkKBnBZNGpywOkGmHyugpahz8%2F24OczJw8xjONPEjPfF%2FMN3aEJKDXyKYBnCEAQAA
Another Delay in Japan, no worse than USA we expected a faster PMDA ..I'm also looking at it as another buying opportunity .. Gil would have NEVER had this happen and they should also given us a update on results for the One Bridge ARDS ..At least publish them so we can at least see ..We need a update from our CEO to clarify ... GOOD LUCK LONGS
It Seems our company have been BUSY behind the scenes .. With that being said the short position is now @18,980,000 up from 15,300,000 and they have 13 days to cover ... Also, Friday's trading volume 1,758,437 versus average 1,460,000 ... GOOD LUCK LONGS
Athersys to Participate in Two Upcoming Investor Conferences .... Company presentations is scheduled at the Locust Walk Stem Cell Conference, April 11, and at the Needham Healthcare Conference, April 13 ..
CLEVELANDAthersys, Inc. (Nasdaq: ATHX) announced today that William (B.J.) Lehmann, President and Chief Operating Officer, will present a corporate overview at the virtual Locust Walk Stem Cell Conference on Monday, April 11, 2022 at 2:00 p.m. ET. Mr. Lehmann will discuss the Company’s investigational clinical product platform, MultiStem® (invimestrocel) cell therapy, which is in late-stage clinical development in the areas of ischemic stroke, acute respiratory distress syndrome (ARDS) and trauma.
Additionally, Dan Camardo, Chief Executive Officer, will present a corporate overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 10:15 a.m. ET. Mr. Camardo will discuss the Company’s clinical programs and its preparations for potential commercialization of MultiStem. The Company’s management team will also participate in one-on-one meetings with institutional investors during the Needham Healthcare Conference.
A live webcast of both presentations can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website. An archived replay of the webcast will be available on the Company's website after the conference for a limited time.
https://www.bizjournals.com/cleveland/search?q=Daniel%20Camardo
Daniel Camardo, the new CEO for Athersys Inc. in Cleveland, is enthusiastic about the prospects for his clinical-stage biotechnology company.
After more than 15 years of developing its adult stem cell therapy, MultiStem, to help stroke, and more recently, acute respiratory distress patients, Athersys appears to be closing in on regulatory approval and the start of commercial production in Japan.
But first Athersys will have to deal with a vexing problem: getting its share price back above the $1 mark for at least 10 consecutive days.
The Cleveland biotech company received a delisting notice from Nasdaq a few weeks ago. This happens when a company's stock on the trading system falls below $1 for 30 consecutive days, Camardo said.
"For folks who have been invested in Athersys for quite some time, I can understand their disappointment, based upon the current share price and recent performance of the company," said the executive, who has delivered numerous therapies to market for other companies over the last two decades.
"We have 180 days in order to work our stock price above a dollar," Camardo said. "We're going to be working hard to change because I do think there's incredible value that still has to be realized, and that's what we're working toward."
The Cleveland biotech's shares started consistently trading below $1 a share starting in December and ended above $1 on only three days this year, including Feb. 1 and 2, which were within two weeks of Camardo being named CEO.
The commercialization pro replaced Athersys co-founder Gil van Bokkelen, who stepped down more than a year ago.
"We're not happy with where the stock price is, and we feel like the company's significantly undervalued," Camardo said.
"We hope that the actions we're taking and the upcoming milestones are going to be able to elevate the stock price to a point where the Nasdaq delisting will no longer be a concern," he said.
Behinds the scenes this is what should be happening at Healios.
1st Healios along with PDMA is reviewing the ARDS’s application to determine and make recommendations on changes to be completed before moving forward.
2nd Treasure trail will be analyze along with the results in 2nd qtr. which Helios has no control over the unbinding analysis will come which is controlled by a 3rd party who overlooks and manages the trial. We have to sit and wait for alllllll work to be completed ... GOOD LUCK LONGS
B.J. Lehmann, President and COO of Athersys, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC. The conference will take place March 28-30, 2022, with pre-recorded presentations available on-demand here: https://lnkd.in/egXzZbRj
A company's moat refers the ability to maintain the competitive advantages that are expected to help it fend off competition and maintain profitability into the future. The MOST exciting aspect's regarding this investment is the differentiation of Multistem from other stem cells specifically MSCs and the ability to use large scale manufacturing. Dan mentioned this and this was one of the BIG reasons he was excited about ATHX future ...When Multistem gets approved Athersys will have a LONG runway WITHOUT competing companies for a LONG TIME. This will make the TECHNOLOGY / CO. more valuable. They ONLY NEED their 1st approval with GREAT Treasure results and MS becomes the STANDARD of CARE that future trails have to exceed. Healios has scheduled meetings coming shortly with approval expected ... GOOD LUCK LONGS
Recapping last week .. CEO Purchased 132,800 @.77 .. BUY rating @$7.00
CEO pointed out the opportunity on hand after carefully studying the potential REWARDS and it OUTWEIGHS the RISK him leaving a 23 Billion dollar company. He met with every BOARD MEMBER / DIRECTORS ETC ask ALLLL ??????? about the opportunities and challenges facing the company. Commercialization is a TOP Priority and he also reviewed all preclinical and clinical studies, especially MASTERS-1 in detail to the point that he took time to speak to several physicians who treat stroke and acute respiratory distress syndrome. He also spoke to several consultants regarding cell therapy space to better understand the manufacturing and regulatory challenges facing ahead in the industry. Dan did PLENTY due diligence before he CONFIRMED his INTEREST as the NEW CEO and LEADER in place. IMAGINE someone LEAVING a BILLION DOLLAR COMPANY and ACCEPTING a JOB at Athersys and the challenges ahead. Going forward with the technical / executive teams which includes several NEW members with further support commercialization plans with Healios. THE BEST IS YET TO COME ... GOOD LUCK LONGS
A friend said 3 which that's about to change is projected to report quarterly loss at $0.18 per share on revenue of $40.26 million.
So much to discuss this up coming week Healios announcing that they're going to be sharing top-line data so we're waiting for that readout. We are also continuing our trial's in Western Europe, the U.S. / Australia and Taiwan. With this being said sometime this year is the target ... GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/td2d50/dr_robert_w_mays_podcast_biotech_iq/?%24deep_link=true&correlation_id=46e29452-ded1-4e0e-8a5b-2ccaba236253&post_fullname=t3_td2d50&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22Q3UrEMBCFn6bedX%2BStqiwyIKID%2BCFd0OazLaD%2BTOZUn17p657JyTk8B3OmSEzc66P%2B31B54h3Juedp%2Fix1%2FmpUZ3OJwRT70SmQhNF42Ep%2FjRvqUafG%2FUiZ13X3V%2FepiCgyD2%2Fvb7LIyBg5CqSnXL9QYQrUNKIhWGFYL4r5OSsqQwjJUY7A31uxVq6O4eYYduo0c9cFmzUYFMp6A1TikBOeDegeuh61Tp0x7bDA7b3ph9bZa0ZjdKD6rXkcpIRl8X7aAJudRpuK109ig6
Athersys Employee Appreciation post--with a nice comment from the new CEO .. GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/t70w9m/athersys_employee_appreciation_postwith_a_nice/?%24deep_link=true&correlation_id=2ece13ee-35ac-47f7-8ae3-d30e16c22f1a&post_fullname=t3_t70w9m&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22QzWrDMBCEn8a92Y4tN24DoQRK6QP00JtYpHW8VH9Ia9y8fdd1cytIaPiG2Vk0M6dyatuM1hI3kFLjKHy1Kr1U%2FaDSGTWUB5Ex05UCOL1kd563VKUuVf8mZ13X5i9voheQ5V4%2B3j%2FlEeAxcBHJ42F93mzgGXO5FY0%2BuXhDqUgpoyFgikGnWHglnjXoQAa3DiU1g0VMeluuUq%2BcFzGOJuaMbo%2BRFd6jwU4h1uoRTD2M01g%2FAaraqgN2R9P3UweS2yr0tDgXwOM2Tun7drtHweK3GJ2AjJMo9EBOW7pi4R1qAz4BXcP%2FbolLNnj3BC7stYmB5TuE%2FtYwscMfjtFMCIMBAAA%3D
If the market is estimated at only half this number, it would translate to an annual potential market of more than $11 billion per year. Trauma represents another meaningful opportunity where current standard of care is limited and in the U.S ONLY ... Now Include Europe to the mix with allllllll of the above the results in the hospitalization of more than 3+ million people a year. Most people don't realize that in the U.S. trauma represents the leading cause of death with individuals up to the age of 50 SADLY ... Don't forget it's about the massive opportunity to improve clinical care and patient quality of life .. ATHX has the potential and translate to an annual potential market opportunity to make well over $10 billion per year which represents another meaningful opportunity where current standard of care is limited and in the U.S ... The price should be WELL over $18 ... JMO ... GOOD LUCK LONGS
This is very INTERESTING POST and it recognizes ALLLLL the above .. Within a few months results will determine Athersys future and it "WILL BE A WELL WORTH WAIT FOR ALLLLLL YOU LONGS ... Remember Ards conditional in Japan makes this a $5 ALLL DAY what would be the price here ??? GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/t2u8ew/at_peace/?%24deep_link=true&correlation_id=fb1b35ce-4a15-4b8b-a554-317615c47f8a&post_fullname=t3_t2u8ew&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_body&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22PzWrDMBCEn8a92caWnJhCKIFS%2BgA99CbW0joR0R%2FSCrdv33XT3AordviG2UFXolSe%2Bz6jMZY6SKlzNtx6kV6aUYp0QgXliWXM9mIDOFWzO133VCPOzfjGs21b95fX0TPI%2FM4f75%2B8GHgMVFjSWGfcWACphKBxTws%2BIA1iUnttI14pVzYOOuaMDsjGoKxhvi7DIiaNrYRhauUyLy1Mk2zFcDwMk5bHdQbOpVhIrdW5AB73c0I9eu%2BeDQa%2F2BgYZFxZoQfrlLEXLHSHSoNPYC%2Fhf7fEmjU%2BPIaVvNIxEH%2BU6W%2FNEs33Dz2rZ1ZcAQAA